A Quick Look at Today's Ratings for Globus Medical(GMED.US), With a Forecast Between $76 to $105
Globus Medical Is Maintained at Overweight by Piper Sandler
Globus Medical Price Target Cut to $80.00/Share From $100.00 by Piper Sandler
Globus Medical Analyst Ratings
RBC Lowers Price Target on Globus Medical to $95 From $101, Keeps Outperform Rating
Needham Maintains Globus Medical(GMED.US) With Hold Rating
BofA Securities Maintains Globus Medical(GMED.US) With Hold Rating, Cuts Target Price to $78
RBC Capital Sticks to Its Buy Rating for Globus Medical (GMED)
Morgan Stanley Maintains Globus Medical(GMED.US) With Buy Rating, Maintains Target Price $100
Globus Medical's Strategic NVRO Acquisition and Recovery Signs Support Buy Rating Despite Short-term Challenges
Barclays Maintains Globus Medical(GMED.US) With Buy Rating, Maintains Target Price $103
BTIG Maintains Globus Medical(GMED.US) With Buy Rating, Cuts Target Price to $88
Globus Medical (GMED) Gets a Buy From BTIG
Truist Financial Maintains Globus Medical(GMED.US) With Hold Rating, Cuts Target Price to $80
Globus Medical Analyst Ratings
Truist Trims Price Target on Globus Medical to $80 From $82, Keeps Hold Rating
JMP Securities Maintains Globus Medical(GMED.US) With Hold Rating
JMP Securities Reaffirms Their Hold Rating on Globus Medical (GMED)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Globus Medical (GMED) and Vertex Pharmaceuticals (VRTX)
A Quick Look at Today's Ratings for Globus Medical(GMED.US), With a Forecast Between $82 to $100